(Q34569905)

3 August 2017

1 reference

title

Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? (English)

1 reference

3 August 2017

1 reference

1 reference

5

Benjamin Djulbegovic

1 reference

3 August 2017

1

Andrew Bottomley

1 reference

3 August 2017

Ronald Thomas

2

1 reference

3 August 2017

Kristel van Steen

series ordinal

3

1 reference

3 August 2017

Henning Flechtner

series ordinal

4

1 reference

3 August 2017

publication date

1 March 2002

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

volume

3

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

145-153

1 reference

Interpreting the significance of changes in health-related quality-of-life scores.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Reporting on quality of life in randomised controlled trials: bibliographic study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Does recombinant human erythropoietin not only treat anemia but reduce postpartum (emotional) distress as well?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Patients' attitudes regarding out-of-hospital blood transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

The effect of Epoetin alfa on quality of life in anemic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Guidelines for reporting results of quality of life assessments in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Recombinant human erythropoietin in the treatment of the anaemia of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Erythropoietin for anaemia in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Depression in cancer patients: a literature review.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Collecting quality of life data in EORTC clinical trials--what happens in practice?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Evaluation of quality of life in patients receiving treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Comparison of conditional quality of life terminology and visual analogue scale measurements

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Nonspecific effects in longitudinal studies: impact on quality of life measures

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Symptom reporting in cancer patients II: relations to social desirability, negative affect, and self-reported health behaviors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Lessons learned from measuring health-related quality of life in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

Methodologic assessments of quality of life measures in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900677-0

7 January 2021

10.1016/S1470-2045(02)00677-0

Identifiers

DOI

1 reference

3 August 2017

1 reference